Vascular Targeting Agents Therapeutic & Diagnostic Development

Venue: Hyatt Regency Cambridge

Location: Cambridge, Massachusetts, United States

Event Date/Time: Nov 08, 2004 End Date/Time: Nov 09, 2004
Early Registration Date: Aug 30, 2004
Report as Spam


Agents that effect neovasculature have now become mainstream with the approval of Avastin, Genentech’s neutralizing monoclonal antibody against vascular endothelial growth factor (VEGF).To date, there are over 60 agents that have entered the clinic designed to inhibit neovascularization, and well over 100 agents in preclinical development. Although many of these agents do indeed inhibit the formation of tumor vessels (“anti-angiogenic”), not all fit into this designation.

Strategic Research Institute’s inaugural International Conference on Vascular Targeting Agents is aimed at understanding the difference between agents that are anti-angiogenic and anti-vascular in nature, the latter not merely inhibiting the formation of vessels but able to damage existing aberrant vessels.

Work will be presented from all of the major players in the industry along with academic veterans in the field. Focus will further demarcate the difference between normal and tumor vessels, methodologies to identify therapeutic agents which specifically target such aberrant vessels and case studies of therapeutic agents that are both in the clinic along with novel entities in preclinical development.